TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32749096

Group type: EXPERIMENTAL
Intervention: Lentinex® (1–2 mL/day, 1–2 mg beta-glucan)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 35562248

Group type: EXPERIMENTAL
Intervention: Tele-education
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 0
Study: 33452861

Group type: EXPERIMENTAL
Intervention: Marine omega-3s and/or vitamin D supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34246609

Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)-guided treatment strategy
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual structured care
Number of subjects: 130
Study: 32303182

Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 40
Study: 32233611

Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 60
Study: 34506540

Group type: EXPERIMENTAL
Intervention: HIV positive individuals
Number of subjects: 0
Study: 35191902

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with bereaved partners
Number of subjects: 8
Study: 35580191

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg once daily for 3 weeks starting 7 ± 2 days after surgery)
Number of subjects: 582

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 582
Study: 32036718

Group type: EXPERIMENTAL
Intervention: Ambu® AuraOnce™ laryngeal mask (LMA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Endotracheal intubation (ETI)
Number of subjects: 80
Study: 33725020

Group type: EXPERIMENTAL
Intervention: Contingent biofeedback
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Deep breathing
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (viewing a film clip)
Number of subjects: 93
Study: 34034005

Group type: EXPERIMENTAL
Intervention: Reward condition (n = 109) where participants could trade in virtual credits for a bonus after a week of play.
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control condition (n = 104) where the possibility of reward was not presented.
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Both groups (reward and control)
Number of subjects: 213
Study: 34360032

Group type: EXPERIMENTAL
Intervention: Percussion therapy group (PTG)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 24
Study: 37757908

Group type: EXPERIMENTAL
Intervention: NaF+5 %NANO
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: NaF+5 %MICRO
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: NaF
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: NaF+2.5 %NANO
Number of subjects: 100

Group type: COMPARATOR
Intervention: Pla
Number of subjects: 100
Study: 33559437

Group type: EXPERIMENTAL
Intervention: Dragon-tiger fighting needling therapy, applied at Sanyinjiao (SP 6), Zusanli (ST 36), Yinlingquan (SP 9), and Xuehai (SP 10), once daily for 2 courses of 2 weeks each.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pregabalin capsules, 75 mg, twice a day for 2 courses of 2 weeks each.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dragon-tiger fighting needling therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pregabalin capsules
Number of subjects: 60
Study: 32723187

Group type: EXPERIMENTAL
Intervention: Bempegaldesleukin plus nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nivolumab alone
Number of subjects: 0
Study: 35023260

Group type: EXPERIMENTAL
Intervention: nanocurcumin (160 mg/day for 6 days)
Number of subjects: 48

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study: 32888085

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (15 mg/kg/6 h for 3 days)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Intravenous ibuprofen (10-5-5 mg/kg/day)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Number of subjects: 101

Group type: COMPARATOR
Intervention: Intravenous ibuprofen
Number of subjects: 101
Study: 36353670

Group type: EXPERIMENTAL
Intervention: Systane iLux thermal pulsation device
Number of subjects: 119
Study: 33221362

Group type: EXPERIMENTAL
Intervention: IV + IO
Number of subjects: 1007

Group type: COMPARATOR
Intervention: IV
Number of subjects: 1007
Study: 32996330

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (120,000 IU monthly for 6 months)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 120
Study: 616358275

Group type: EXPERIMENTAL
Intervention: Specialized immunonutrition (SIM) providing supplemental L-arginine, fish oil, vitamin A, and nucleotides
Number of subjects: 29

Group type: COMPARATOR
Intervention: Calorie- and nitrogen-matched oral nutrition supplement (ONS)
Number of subjects: 29
Study: 33735832

Group type: COMPARATOR
Intervention: Complex Training (CT)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Balance exercises conducted prior to Complex Training (bCT)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both bCT and CT
Number of subjects: 23
Study: 32020360

Group type: EXPERIMENTAL
Intervention: Triple therapy with bismuth (esomeprazole 20 mg twice a day, amoxicillin 1 g thrice daily, metronidazole 400 mg thrice daily, and bismuth 220 mg twice a day)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Triple therapy without bismuth (esomeprazole 20 mg twice a day, amoxicillin 1 g thrice daily, metronidazole 400 mg thrice daily)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Intent-to-treat analysis with bismuth
Number of subjects: 216

Group type: COMPARATOR
Intervention: Intent-to-treat analysis without bismuth
Number of subjects: 216
Study: 34693836

Group type: EXPERIMENTAL
Intervention: Bimanual abdomen-flank compression for 0 min
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bimanual abdomen-flank compression for 3 min
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bimanual abdomen-flank compression for 7 min
Number of subjects: 90
Study: 33608955

Group type: EXPERIMENTAL
Intervention: Distraction cards group
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Virtual reality group
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study: 33006567

Group type: EXPERIMENTAL
Intervention: eMBCT (online mindfulness-based cognitive therapy)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: eMBCT
Number of subjects: 125
Study: 36198247

Group type: EXPERIMENTAL
Intervention: Pediatric seizure management virtual reality simulator (n=53)
Number of subjects: 105

Group type: COMPARATOR
Intervention: In-person lecture (n=52)
Number of subjects: 105
Study: 33665904

Group type: EXPERIMENTAL
Intervention: BASIC model (clinical variables only)
Number of subjects: 3105

Group type: EXPERIMENTAL
Intervention: EXTENDED model (clinical variables plus laboratory results)
Number of subjects: 3105

Group type: EXPERIMENTAL
Intervention: FULL model (all candidate variables)
Number of subjects: 3105

Group type: COMPARATOR
Intervention: EXTENDED model applied to Luzhou cohort
Number of subjects: 3105
Study: 33189208

Group type: EXPERIMENTAL
Intervention: Dorsal radial artery access
Number of subjects: 970

Group type: COMPARATOR
Intervention: Classical radial artery access
Number of subjects: 970
Study: 34981547

Group type: EXPERIMENTAL
Intervention: SAMe enteric-coated tablets in fasting condition
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SAMe enteric-coated tablets in postprandial condition
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SAMe enteric-coated tablets in both conditions
Number of subjects: 24
Study: 33860985

Group type: EXPERIMENTAL
Intervention: Cervical length increased between admission and 48 hours later
Number of subjects: 164

Group type: COMPARATOR
Intervention: Cervical length decreased between admission and 48 hours later
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Greater absolute cervical length after 48 hours
Number of subjects: 164
Study: 35966574

Group type: EXPERIMENTAL
Intervention: Methylprednisolone-ropivacaine
Number of subjects: 132

Group type: COMPARATOR
Intervention: Ropivacaine alone
Number of subjects: 132
Study: 34952916

Group type: EXPERIMENTAL
Intervention: Femtosecond laser‐assisted capsulotomy (FLACS) performed before lens fragmentation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Femtosecond laser‐assisted capsulotomy (FLACS) performed after lens fragmentation
Number of subjects: 20
Study: 36417649

Group type: EXPERIMENTAL
Intervention: Online breastfeeding counseling
Number of subjects: 151
Study: 32305492

Group type: EXPERIMENTAL
Intervention: Probiotics + FOS
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 34125632

Group type: EXPERIMENTAL
Intervention: B/F/TAF (BPT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: DTG/ABC/3TC (DPT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both tablets
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: EoS of either tablet
Number of subjects: 50
Study: 34344675

Group type: EXPERIMENTAL
Intervention: OMPRIS intervention (4-week psychological intervention based on motivational interviewing, addiction therapy, behavioral therapy techniques, and social counseling)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: OMPRIS intervention
Number of subjects: 162

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 162
Study: 32721437

Group type: EXPERIMENTAL
Intervention: Budesonide Orodispersible Tablet (BOT) 0.5 mg twice daily
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Budesonide Orodispersible Tablet (BOT) 1.0 mg twice daily
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 35388956

Group type: EXPERIMENTAL
Intervention: RelyX U200 Automix (RXU) self‐adhesive resin cement after selective enamel etching
Number of subjects: 53

Group type: COMPARATOR
Intervention: G‐CEM LinkForce (GCL) adhesive resin cement with G‐Premio Bond in selective etch mode
Number of subjects: 53

Group type: COMPARATOR
Intervention: Both RXU and GCL groups
Number of subjects: 53
Study: 33445082

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 32441571

Group type: EXPERIMENTAL
Intervention: Inverse ratio ventilation combined with lung-protective ventilation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 80
Study: 35653117

Group type: COMPARATOR
Intervention: Beta carotene
Number of subjects: 3882

Group type: EXPERIMENTAL
Intervention: Lutein/zeaxanthin
Number of subjects: 3882

Group type: EXPERIMENTAL
Intervention: ω-3 fatty acids
Number of subjects: 3882

Group type: EXPERIMENTAL
Intervention: Lutein/zeaxanthin (restricted to beta carotene group)
Number of subjects: 3882

Group type: COMPARATOR
Intervention: Lutein/zeaxanthin vs beta carotene
Number of subjects: 3882

Group type: COMPARATOR
Intervention: Low zinc
Number of subjects: 3882

Group type: COMPARATOR
Intervention: No beta carotene
Number of subjects: 3882
Study: 32641735

Group type: EXPERIMENTAL
Intervention: HIV-infected children with SAM
Number of subjects: 167

Group type: COMPARATOR
Intervention: Children with SAM without HIV
Number of subjects: 167
Study: 34288609

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray plus an oral antidepressant (ESK + AD)
Number of subjects: 518

Group type: COMPARATOR
Intervention: Oral antidepressant plus placebo (AD + PBO)
Number of subjects: 518
Study: 32043763

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus Fulvestrant
Number of subjects: 669

Group type: COMPARATOR
Intervention: Placebo plus Fulvestrant
Number of subjects: 669
Study: 35943958

Group type: EXPERIMENTAL
Intervention: Group-based eight-week cognitive-behavioral therapy (CBT) treatment program
Number of subjects: 62

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 62
Study: 34467684

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) treatment
Number of subjects: 1102

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 1102
Study: 35083739

Group type: EXPERIMENTAL
Intervention: Tramadol chewable tablet (1 mg/kg)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Tramadol chewable tablet
Number of subjects: 141

Group type: COMPARATOR
Intervention: Tramadol hydrochloride oral liquid (1 mg/kg)
Number of subjects: 141
Study: 34042185

Group type: EXPERIMENTAL
Intervention: Multiparametric clinical‐radiomics model combining MRI‐reported extramural vascular invasion (EMVI) status and a Radiomics score for LVI/PNI estimation
Number of subjects: 263
Study: 35190434

Group type: EXPERIMENTAL
Intervention: web-based low carbohydrate diet (LCD) intervention plus standard care
Number of subjects: 100

Group type: COMPARATOR
Intervention: standard care only
Number of subjects: 100
Study: 34542313

Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage
Number of subjects: 6

Group type: COMPARATOR
Intervention: Compression
Number of subjects: 6
Study: 36109036

Group type: EXPERIMENTAL
Intervention: CRP point-of-care testing (POCT)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Usual care without CRP POCT
Number of subjects: 241
Study: 34352597

Group type: EXPERIMENTAL
Intervention: Healing Meditation
Number of subjects: 55
Study: 32841219

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclophosphamide-azathioprine (CYC/AZA)
Number of subjects: 0
Study: 34764215

Group type: EXPERIMENTAL
Intervention: Adapted ketogenic diet (AKD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Common diet
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Seven-day fasting
Number of subjects: 60
Study: 34963451

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) for 1 week (Group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT) for 2 weeks (Group C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Postoperative wound management alone with gauze exchange (Group A)
Number of subjects: 30
Study: 34864084

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 1070

Group type: COMPARATOR
Intervention: Non-febuxostat
Number of subjects: 1070
Study: 34473033

Group type: EXPERIMENTAL
Intervention: Combined general + epidural anesthesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 80
Study: 32661293

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 36204223

Group type: EXPERIMENTAL
Intervention: Esketamine 20 mg (diluted with 0.9% normal saline, 1 ml)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Esketamine 12 mg (diluted with 0.9% normal saline, 1 ml)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Esketamine 4 mg (diluted with 0.9% normal saline, 1 ml)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Normal saline (1 ml)
Number of subjects: 252
Study: 33835103

Group type: EXPERIMENTAL
Intervention: Relaxation exercises
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (standard pain management medication)
Number of subjects: 146
Study: 35666489

Group type: EXPERIMENTAL
Intervention: Strain-counterstrain technique (SCS) combined with standard therapy (active range of motion, stretching exercises, and postural correction exercises)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard therapy only (active range of motion, stretching exercises, and postural correction exercises)
Number of subjects: 60
Study: 33804967

Group type: EXPERIMENTAL
Intervention: 30-min aqua-cycling exercise session (WAT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: land-cycling session at the same heart rate and isoenergetic to WAT (LAND-Iso)
Number of subjects: 20

Group type: COMPARATOR
Intervention: rest condition (CONT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 30-min land-cycling exercise session (LAND)
Number of subjects: 20
Study: 34919626

Group type: EXPERIMENTAL
Intervention: Zygomatic implant combined with 'three-dimensional ring'-supported prosthetics (group 3)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional prostheses with a clasp (group 1)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Regular implant with obturator removal (group 2)
Number of subjects: 45
Study: 33574139

Group type: EXPERIMENTAL
Intervention: IgM titre‐based treatment with a personalised daily dose based on IgM serum titre aimed at achieving serum titres above 100 mg/dL
Number of subjects: 356

Group type: COMPARATOR
Intervention: Standard treatment group receiving IgM enriched preparation daily for three consecutive days at the standard dose of 250 mg/kg
Number of subjects: 356
Study: 32267714

Group type: EXPERIMENTAL
Intervention: 10‐20‐30 training (3 × 5 × 10‐s sprint followed by 30 and 20 s of low‐ to moderate‐intensity cycling, interspersed by 3 min of rest)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10‐20‐30 training
Number of subjects: 18
Study: 33009187

Group type: EXPERIMENTAL
Intervention: Prophylactic fibrinogen concentrate (Haemocomplettan P) at a mean dose of 79 mg kg‐1 body weight
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Prophylactic fibrinogen concentrate (Haemocomplettan P)
Number of subjects: 114
Study: 33263136

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS)
Number of subjects: 250
Study: 36294132

Group type: EXPERIMENTAL
Intervention: Mesh closure
Number of subjects: 790

Group type: COMPARATOR
Intervention: Standard closure
Number of subjects: 790
Study: 34746040

Group type: EXPERIMENTAL
Intervention: SIM evening group (SIM addition to PEG in the evening of the day prior to colonoscopy)
Number of subjects: 419

Group type: COMPARATOR
Intervention: SIM morning group (SIM addition to PEG in the morning of colonoscopy)
Number of subjects: 419
Study: 33493256

Group type: EXPERIMENTAL
Intervention: MEDI6012 120 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: MEDI6012 300 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: IV-push 300 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 32331011

Group type: EXPERIMENTAL
Intervention: Active rTMS treatment (3500 pulses at 10 Hz to left dlPFC and 1500 pulses at 1 Hz to right dlPFC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham rTMS treatment
Number of subjects: 26
Study: 35107141

Group type: EXPERIMENTAL
Intervention: Ampicillin and Gentamicin
Number of subjects: 59
Study: 36178716

Group type: EXPERIMENTAL
Intervention: CDSS addressing physical activity and diet
Number of subjects: 5331

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 5331
Study: 34635000

Group type: EXPERIMENTAL
Intervention: Elastic taping
Number of subjects: 51

Group type: COMPARATOR
Intervention: Rigid taping
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo taping
Number of subjects: 51
Study: 32217010

Group type: EXPERIMENTAL
Intervention: Portocaval shunt (PCS)
Number of subjects: 231

Group type: COMPARATOR
Intervention: No portocaval shunt (Control)
Number of subjects: 231
Study: 36178864

Group type: EXPERIMENTAL
Intervention: Copeptin levels before and after hemodialysis
Number of subjects: 84

Group type: COMPARATOR
Intervention: Hemodialysis treatment
Number of subjects: 84
Study: 34669907

Group type: EXPERIMENTAL
Intervention: Modified measurement method
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard measurement method
Number of subjects: 88
Study: 32501814

Group type: EXPERIMENTAL
Intervention: Ethanol-containing gel with 5% urea applied twice daily for 17 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Untreated control forearm
Number of subjects: 20
Study: 616115932

Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA) administered via a mostly self‐administered, tablet‐based system within 72 hours of hospitalization.
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Provision of GA results to treating clinicians within 24 hours of GA administration.
Number of subjects: 79
Study: 35660128

Group type: EXPERIMENTAL
Intervention: FEE intervention
Number of subjects: 1260

Group type: EXPERIMENTAL
Intervention: FEE + MFG interventions
Number of subjects: 1260

Group type: COMPARATOR
Intervention: Control condition (bolstered standard of care)
Number of subjects: 1260
Study: 33249198

Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 890

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 890
Study: 34125060

Group type: EXPERIMENTAL
Intervention: Single transducer hand-carried ultrasound (HCU)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Multiple transducer cart-based ultrasound (CBU)
Number of subjects: 29
Study: 32512752

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Low Glycemic Index diet (LGID)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Low Glycemic Index Mediterranean diet (LGIMD)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Severe NAFLD subjects
Number of subjects: 237
Study: 34878412

Group type: EXPERIMENTAL
Intervention: Nasal mask
Number of subjects: 574

Group type: COMPARATOR
Intervention: Nasal cannula
Number of subjects: 574
Study: 32391167

Group type: EXPERIMENTAL
Intervention: Body Soul and Spirit intervention
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Body Soul and Spirit Plus (includes faith-based text messages)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control arm (information leaflets)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 12
Study: 35588737

Group type: EXPERIMENTAL
Intervention: IGF‐1 levels in Group 3 (severe NAFLD)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: SDSIGF1 levels in Group 3 (severe NAFLD)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: SDSIGF1 levels
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Liver Diameter, FPG, ALT, AST, GGT
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Pre- and postoperative values in all groups
Number of subjects: 316
Study: 34746161

Group type: EXPERIMENTAL
Intervention: Washed Microbiota Transplantation at day 1 (WMT-DAY1)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Washed Microbiota Transplantation at day 8 (WMT-DAY8)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Clinical remission rate at day 15 (WMT-DAY1)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Clinical remission rate at day 15 (WMT-DAY8)
Number of subjects: 19